Related tags: Lonza, CBD, Manufacturing, Contract manufacturing, CNS, Multiple sclerosis, Parkinson’s disease Lonza will be supporting Emerald Health Pharmaceuticals through clinical trials of its synthetic derivative of cannabidiol (CBD), by manufacturing the liquid encapsulation solution to provide trial participants with current good manufacturing practice (cGMP) quality therapies in an accessible format. Per the agreement, Lonza will synthesize the active pharmaceutical ingredient (API) and drug substance (VCE -004.8) to develop the drug product, EHP-101 as liquid-filled capsules. Christian Dowdeswell, head of dosage form and delivery systems, Lonza, told us that from an API manufacturing perspective there are no differences between the manufacture of a product with CBD and a traditional manufacturing process of a small molecule. The development and manufacture of this drug substance will occur across Lonza’s global network, including its sites in Nansha, China, Edinburgh, UK, and Ploermel, France. Because of this globalization, the development and manufacture of the drug is more accessible, “Depending on the approving authority or country regulations, some CBD-based m...